Serious gastric perforation after second stereotactic body radiotherapy for peripheral lung cancer that recurred after initial stereotactic body radiotherapy: a case report

Hotaka Nonaka1*, Hiroshi Onishi1, Masatoki Ozaki2, Kengo Kuriyama1, Takafumi Komiyama1 and Ryo Saito3

Abstract

Background: In recent reports, re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiation therapy resulted in several serious toxicities. Serious non-lung toxicities were observed mostly in patients with central tumors, but we experienced a case of fatal gastric perforation after a second stereotactic body radiotherapy in a patient with a peripheral lung tumor.

Case presentation: An 83-year-old Asian man was diagnosed with T2N0M0 lung cancer in the form of squamous cell carcinoma in the lower lobe of his left lung. He was treated with stereotactic body radiotherapy of 40 Gy in 4 fractions and the tumor decreased in size in partial response. The local tumor recurred 8 months after the first stereotactic body radiotherapy, and he was re-irradiated with a second stereotactic body radiotherapy of 50 Gy in 4 fractions. A Sengstaken–Blakemore tube was inserted below his diaphragm by laparoscopic surgery before the second stereotactic body radiotherapy in order to reduce the stomach dose by keeping his stomach apart from the tumor. Two months after the second stereotactic body radiotherapy, he developed fatal gastric perforation and gastroleural fistula penetrating his diaphragm.

Conclusions: To the best of our knowledge, this is the first report about a gastric perforation after stereotactic body radiotherapy for lung tumors and it warns of serious complication of stereotactic body radiotherapy in not only centrally located but also peripherally located tumors like in this case.

Keywords: Stereotactic body radiotherapy, Re-irradiation, Lung cancer, Gastric perforation

Background

Stereotactic body radiotherapy (SBRT) plays a major role in the treatment of early-stage non-small cell lung cancer and oligometastatic lung tumors [1]. In recent reports, SBRT has also been performed for lung tumors in patients previously treated with thoracic radiation therapy [2–17]. Although most toxicities after re-irradiation with SBRT for these patients were grade 3 or less, several reports showed serious toxicities of grade 4 to 5 [4, 6, 7, 10, 11, 17] (Table 1). In these reports, most serious non-lung toxicities were observed in cases with central lung tumors. However, we experienced a case of fatal gastric perforation after the second SBRT for a peripheral lung tumor that recurred after the first SBRT.

Case presentation

An 83-year-old Asian man with a left lung tumor was referred to our hospital for SBRT in 2008. He had no clinical symptoms. Chest computed tomography (CT) showed a 3.5 cm-sized tumor located close to his left diaphragm. Magnetic resonance imaging of his head and fluorodeoxyglucose-positron emission tomography...
(FDG-PET)/CT showed no metastatic lesions. The maximum standardized uptake value (SUVmax) of the tumor on FDG-PET/CT was 6.9. The serum cytokeratin-19 fragment (CYFRA 21-1) level was elevated to 8.7 ng/mL. A transbronchial lung biopsy revealed squamous cell carcinoma. The lung cancer was staged at T2N0M0 based on the sixth TNM classification of malignant tumors. He had undergone upper lobectomy for stage I squamous cell lung cancer in 1993, and his medical history also included hypertension, atrial fibrillation, renal sclerosis, and chronic bronchitis with low respiratory function. Radical left lower lobectomy was not applicable because of his advanced age, history of left upper lobectomy, and low respiratory function; therefore, he selected SBRT.

SBRT was performed with the self-breath-holding technique using a respiratory monitoring system. Image guidance was performed using a CT-on-rails system for all sessions. A total dose of 40 Gy in 4 fractions was delivered to 95% of the planning target volume. The details of irradiation are shown in Table 2. The maximum dose (Dmax) in the stomach volume was 45.8 Gy. The dose distribution and dose volume histogram of his stomach are shown in Figs. 1a and 2a, respectively. Immediately after the completion of SBRT, he developed vomiting and upper abdominal pain, and he was

**Table 1** Serious toxicities after re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiotherapy

| Authors and Reference number | Number of patients | Tumor location (central/peripheral) | Initial irradiation dosea | Re-SBRT dosea | Non-lung toxicities of grade 4–5 (tumor location) | Lung toxicities of grade 4–5 |
|-------------------------------|--------------------|---------------------------------|--------------------------|--------------|-----------------------------------------------|-----------------------------|
| Peulen et al. [4]             | 29                 | 11/21                           | 30 Gy/2 Fr               | 30 Gy/2 Fr   | G5 hemoptysis: 3 pts (central)                | None                        |
|                               |                    |                                 | 40 Gy/4 Fr               | 40 Gy/5 Fr   | G4 othersb: 2 pts (central)                   |                             |
| Liu et al. [6]                | 72                 | 4/68                            | 63 Gy/Conv               | 50 Gy/4 Fr   | NA                                            | G5 pneumonitis: 1 pt        |
| Reyngold et al. [7]           | 39                 | NA                             | 61 Gy/Conv               | 70.4 Gy (BED10) | G4 skin: 1 pt (peripheral)                   | None                        |
| Kilburn et al. [10]          | 33                 | 17/16                           | 66 Gy/33 Fr              | 50 Gy/10 Fr  | G5 aorta-esophageal fistula: 1 pt (central)  | None                        |
| Trovo et al. [11]            | 17                 | 17/0                            | 50-60 Gy/20–30 Fr        | 30 Gy/5–6 Fr | G5 hemoptysis: 1 pt (central)                 | G5 pneumonitis: 1 pt        |
| Parks et al. [17]            | 27                 | 18/11                           | 64.8 Gy/Conv             | 50 Gy/5 Fr   | G4 chest wall pain: 1 pt                     | None                        |

Abbreviations: BED10 biologically effective dose (α/β = 10), Conv conventional fractionation, Fr fractions, G grade, NA not available, pt patient, Re-SBRT re-irradiation with stereotactic body radiotherapy

*Median dose or frequently used dose

bVena cava superior stenosis and fistula between the trachea and gastric tube developed in a case with a recurrent tumor at the carina

SBRT was performed for a right lung tumor in a patient who had received contralateral lung irradiation [19]

**Table 2** Details of irradiations in the present case

|                          | First SBRT | Second SBRT |
|--------------------------|------------|-------------|
| Total dose (Gy)          | 40         | 50          |
| Fractions                | 4          | 4           |
| Prescription             | PTV D95    | Isocenter   |
| Target volume            | CTV = GTV  | CTV = GTV   |
|                          | ITV = CTV + 1 mm | ITV = CTV + 4 mm |
|                          | PTV = ITV + 5 mm | PTV = ITV + 5 mm |
| Leaf margin (mm)         | 5          | 0           |
| Beam energy (MV)         | 6          | 6           |
| Beam arrangement         | Non-coplanar dynamic arcs | Non-coplanar dynamic arcs |
| Dose calculation         | Superposition | Superposition |

Abbreviations: CTV clinical target volume, GTV gross tumor volume, ITV internal target volume, PTV D95 dose to 95% of the planning target volume, SBRT stereotactic body radiotherapy

**Fig. 1** Dose distributions on sagittal images in stereotactic body radiotherapy. a The first stereotactic body radiotherapy. b The second stereotactic body radiotherapy. The white line (arrow) and green line (arrowhead) show the stomach and the balloon of the Sengstaken–Blakemore tube, respectively
consequently treated with a histamine H2-receptor antagonist. Two months after SBRT, CT revealed a partial response of the lung tumor, and the serum CYFRA 21-1 level had decreased to the normal range. However, approximately 3 months after SBRT, he developed hematemesis. Endoscopy showed a deep ulcer on the fornix of his stomach (Fig. 3a), and he was treated with a proton pump inhibitor. Eight months after SBRT, repeated endoscopy showed an intractable ulcer (Fig. 3b). Around the same time, local recurrence was diagnosed by tumor progression on CT images accompanying high uptake on FDG-PET/CT (SUVmax, 4.9) and elevation of the serum CYFRA 21-1 level. A 4.5 cm-sized recurrent tumor was observed, in contact with his left diaphragm, while metastatic disease was not noted. The recurrent tumor did not cause any symptoms. He did not accept the risk of salvage segmentectomy, and radiofrequency ablation was not applicable because of the large tumor size. Thus, he selected re-irradiation with SBRT after receiving information regarding the possibility of serious toxicity due to repeated SBRT and providing informed consent.

The second SBRT was performed 11 months after the first SBRT. A Sengstaken–Blakemore tube was inserted below his diaphragm by laparoscopic surgery before the second SBRT in order to keep his stomach away from the tumor. The balloon was expanded with 200 ml of normal saline. A total dose of 50 Gy in 4 fractions was delivered to the isocenter. The Dmax of the stomach was 48.0 Gy, but we considered that the high-dose region differed from the previous one treated with the first SBRT, based on the change of the stomach shape by the Sengstaken–Blakemore tube. The dose distribution and dose volume histogram of the stomach are shown in Figs. 1b and 2b, respectively. One of four sessions was performed during free-breathing because of his depressed level of consciousness. He was irradiated with verification of tumor reproducibility using a respiratory monitoring system.

One month after the second SBRT, he was hospitalized with melena and anemia. An endoscopy revealed a deep ulcer in the same region as after the first SBRT, and he was treated with a proton pump inhibitor (Fig. 4a). Subsequently, he developed left thoracic empyema, and a tube was inserted into his left thorax for drainage. Two months after the second SBRT, a gastric perforation and gastropleural fistula penetrating his diaphragm were suspected because of food debris being observed in his drainage tube. He was treated conservatively because of inoperability. Three months after the second SBRT, an endoscopy showed a large gastric perforation and gastropleural fistula (Fig. 4b, c), and he died of multiple organ failure with thoracic empyema.

Discussion
In recent reports, re-irradiation with SBRT for lung tumors previously treated with thoracic radiation therapy resulted in several serious toxicities [4, 6, 7, 10, 11, 17]. Most cases of serious non-lung toxicities were observed.
in patients with central tumors. Peulen et al. reported the following serious toxicities after re-irradiation with SBRT for central tumors: three cases of grade 5 hemoptysis and one case of grade 4 vena cava superior stenosis and grade 4 fistula between the trachea and gastric tube [4]. Kilburn et al. reported a case of grade 5 aorta-esophageal fistula after re-irradiation with SBRT for a central tumor previously treated with chemoradiotherapy [10], while Trovo et al. reported a case of fatal hemoptysis after re-irradiation with SBRT for central disease [11].

In our case, the patient had a peripheral tumor that was treated twice with SBRT, and consequently developed serious gastric perforation. Referring to the endoscopic images, we suspected that this resulted from the high dose of the second SBRT delivered to the same gastric region as the first SBRT. Although we tried to extend the distance between the stomach and the tumor and to change the high-dose region in the stomach by inserting a spacer to reduce the stomach dose, we could not sufficiently extend the distance because of coalescent resulting from the first SBRT.

Bae et al. analyzed the predictors for severe gastroduodenal toxicity in patients treated with SBRT using 33 to 60 Gy (median, 45 Gy) in 3 fractions for abdominopelvic malignancies [18]. Forty patients, including two and one patients with grade 4 gastric perforation and grade 3 gastric ulcer, respectively, were reviewed. The authors suggested that Dmax values of 35 and 38 Gy were respectively associated with 5% and 10% probabilities of severe gastroduodenal toxicity. In our case, the Dmax values in the first and second SBRT were 45.8 and 48.0 Gy, respectively. Considering that the maximum doses per fraction in our case and the predictive doses suggested by Bae et al. [18] were similar, the Dmax values in our first and second SBRT were higher than the above doses. We calculated the accumulated dose of the stomach in the first and second SBRT using MIM Maestro™ (version 6.5, MIM Software Inc., Cleveland, OH, USA). Rigid registration was used to create fusion CT images focusing on the fornix of the stomach. The Dmax of the stomach in the summed plan was 83.5 Gy, which was considerably higher than the predictive doses.

Finally, although a detailed case presentation on serious gastric perforation after SBRT for lung tumors has not yet been reported, based on the present case, we conclude that we should carefully evaluate the stomach doses in both the first and second SBRT. Moreover, we should also be cautious of the toxicity after the first SBRT, and should observe the stomach with endoscopy immediately before the second SBRT.

**Conclusions**
To the best of our knowledge, this is the first report about a gastric perforation after SBRT for lung tumors. Our case of re-irradiation with SBRT for a lung tumor suggests that it is necessary to pay attention to not only the tumor location in the lung but also to the doses to the normal tissue and any toxicity after initial irradiation.

**Abbreviations**
CT: Computed tomography; CYFRA 21-1: Cytokeratin-19 fragment; Dmax: Maximum dose; FDG-PET: Fluorodeoxyglucose-positron emission tomography; SBRT: Stereotactic body radiotherapy; SUVmax: Maximum standardized uptake value

**Acknowledgements**
We thank Makoto Ohara, Shinji Taka, and Akihiro Yamazaki for their support.

**Funding**
Not applicable.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Authors’ contributions**
HO and KK were major contributors in writing the manuscript. MO contributed the observation of the patient and collection of the patient’s data. TK performed the first SBRT. RS performed the second SBRT. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Written informed consent was obtained from the patient’s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Competing interests**
The authors declare that they have no competing interests.
References

1. Franks KN, Jain P, Snee MP. Stereotactic ablative body radiotherapy for lung cancer. Clin Oncol (R Coll Radiol). 2015;27:280–9.

2. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;76:387–93.

3. Seung SK, Solljem M. Salvage SBRT for previously irradiated lung cancer. J Cancer Ther. 2011;2:190–5.

4. Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol. 2011;101:260–6.

5. Triakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol. 2012;7:1462–5.

6. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:1017–23.

7. Reynold M, Wu AJ, McLane A, Zhang Z, Hsu M, Stein NF, et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol. 2013;8:99.

8. Meijneke TR, Pettit SF, Wentzler D, Hoogeman M, Nuyten J. Reirradiation and stereotactic radiotherapy for tumors in the lung: Dose summation and toxicity. Radiother Oncol. 2013;107:423–7.

9. Valkah V, Miyamoto C, Micalyi G, Chan P, Neicu T, Li S. Repeat stereotactic body radiation therapy for patients with pulmonary malignancies who had previously received SBRT to the same or an adjacent tumor site. J Cancer Res Ther. 2013;9:680–5.

10. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014;110:505–11.

11. Trovo M, Minatelli E, Duroff E, Polesel J, Avanzo M, Baresic T, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;88:1114–9.

12. Hearn JW, Videtic GM, Djejni T, Stepheks KL. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT. Int J Radiat Oncol Biol Phys. 2014;88:1025–6.

13. Owen D, Olivier KR, Song L, Mayo CS, Miller RC, Nelson K, et al. Safety and tolerability of SBRT after high-dose external beam radiation to the lung. Front Oncol. 2015;4:376.

14. Patel NR, Lanciano R, Sura K, Yang J, Lamond J, Feng J, et al. Stereotactic body radiotherapy for reirradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol. 2015;4:65–70.

15. Nishimura S, Takeda A, Sanuki N, Yoshida S, Shigematsu N. Dose-escalated stereotactic body radiotherapy (SBRT) as a salvage treatment for two cases with relapsed peripheral lung cancer after initial SBRT. J Thorac Oncol. 2015;10:69–71.

16. Amendola BE, Amendola MA, Perez N, Wu X, Suarez JB. Local failure after primary radiotherapy in lung cancer: is there a role for SBRT? Rep Pract Oncol Radiother. 2015;20:440–5.

17. Parks J, Moecker G, Woo S, Dunlap NE. Stereotactic body radiation therapy as salvage for intrathoracic recurrence in patients with previously irradiated locally advanced non-small cell lung cancer. Am J Clin Oncol. 2016;39:147–53.

18. Bae SH, Kim MS, Cho CK, Kang J-K, Lee SY, Lee K-N, et al. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int J Radiat Oncol Biol Phys. 2012;84:469–74.

19. Hoppe BS, Lasar B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke ED, et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys. 2008;72:1283–6.